Calquence (acalabrutinib) vs Velexbru (tirabrutinib hydrochloride)
Calquence (acalabrutinib) vs Velexbru (tirabrutinib hydrochloride)
Calquence (acalabrutinib) and Velexbru (tirabrutinib hydrochloride) are both Bruton's tyrosine kinase (BTK) inhibitors used in the treatment of certain blood cancers. Calquence is approved for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia in some regions, offering a well-studied option with a known efficacy and side effect profile. Velexbru, while also a BTK inhibitor, may have different approvals and clinical uses depending on the region, and patients should consult with their healthcare provider to determine the most appropriate treatment based on their specific medical condition, the drug's approval status, and their individual health profile.
Difference between Calquence and Velexbru
| Metric | Calquence (acalabrutinib) | Velexbru (tirabrutinib hydrochloride) |
|---|---|---|
| Generic name | Acalabrutinib | Tirabrutinib hydrochloride |
| Indications | Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL), Mantle cell lymphoma (MCL) | Relapsed or refractory primary central nervous system lymphoma (PCNSL) |
| Mechanism of action | Bruton's tyrosine kinase (BTK) inhibitor | Bruton's tyrosine kinase (BTK) inhibitor |
| Brand names | Calquence | Velexbru |
| Administrative route | Oral | Oral |
| Side effects | Headache, diarrhea, muscle pain, neutropenia, anemia, thrombocytopenia, etc. | Fever, neutropenia, thrombocytopenia, rash, fatigue, etc. |
| Contraindications | Hypersensitivity to acalabrutinib or its excipients | Hypersensitivity to tirabrutinib or its excipients |
| Drug class | BTK inhibitor | BTK inhibitor |
| Manufacturer | AstraZeneca | Ono Pharmaceutical Co., Ltd. |
Efficacy
Efficacy of Calquence (Acalabrutinib) in Treating Lymphoma
Calquence (acalabrutinib) is a Bruton tyrosine kinase (BTK) inhibitor that has shown efficacy in the treatment of certain types of lymphoma, particularly mantle cell lymphoma (MCL). In clinical trials, acalabrutinib has demonstrated a high overall response rate in patients with relapsed or refractory MCL. The drug works by inhibiting the BTK enzyme, which is essential for the growth and survival of malignant B cells. By targeting this pathway, acalabrutinib can reduce the proliferation of cancerous cells and induce apoptosis, leading to tumor shrinkage and clinical response in patients.
The efficacy of acalabrutinib in lymphoma was highlighted in a pivotal phase 2 clinical trial, where the majority of patients with relapsed or refractory MCL responded to the treatment, with a significant proportion achieving complete remission. The duration of response for these patients was also notable, with many experiencing prolonged periods of disease control. This has established acalabrutinib as an important treatment option for patients with this challenging form of lymphoma.
Efficacy of Velexbru (Tirabrutinib Hydrochloride) in Treating Lymphoma
Velexbru (tirabrutinib hydrochloride) is another BTK inhibitor that has been studied for its efficacy in treating lymphomas, particularly in patients with relapsed or refractory non-Hodgkin lymphoma (NHL). Similar to acalabrutinib, tirabrutinib targets the BTK enzyme, disrupting the signaling pathways necessary for the growth and survival of B-cell lymphomas. Clinical trials have demonstrated that tirabrutinib can induce responses in a significant number of patients with B-cell malignancies, including those who have failed previous therapies.
In a phase 2 clinical trial, tirabrutinib showed promising results in patients with Waldenström's macroglobulinemia, a rare type of non-Hodgkin lymphoma. The trial reported a high overall response rate, with many patients achieving partial or complete remission. These findings suggest that tirabrutinib could be a valuable therapeutic option for patients with B-cell lymphomas who have limited treatment choices due to disease progression or treatment resistance.
Regulatory Agency Approvals
Calquence
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
-
Therapeutic Goods Administration (TGA), Australia
Velexbru
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Access Calquence or Velexbru today
If Calquence or Velexbru are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us